Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Phreesia, Inc. on behalf of purchasers of Phreesia common stock between May 8, 2025 and March 30, 2026. The complaint alleges the company and its executives made false or misleading statements and failed to disclose slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment. On December 8, 2025, CFO Balaji Gandhi provided fiscal 2027 revenue guidance of $545 million to $559 million, but on March 30, 2026, the company reduced that guidance to $510 million to $520 million, citing weaker pharmaceutical marketing commitments and shorter visibility. The stock fell 21 to 28 percent on the revised outlook. Investors have until July 13, 2026 to seek appointment as lead plaintiff.
Phreesia IncClass action lawsuit alleging false statements and reduced guidance due to slowing demand, causing stock to fall 21-28%.